3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
Ipilimumab
98
pembrolizumab
84
Nivolumab
82
aldesleukin
51
Cyclophosphamide
49
Interleukin-2
38
fludarabine phosphate
31
Vemurafenib
31
Dacarbazine
31
dabrafenib
29
trametinib
28
Temozolomide
26
fludarabine
25
CTLA-4 Antigen
18
Bevacizumab
18
Radiosurgery
15
Paclitaxel
15
Carboplatin
14
encorafenib
13
binimetinib
13
Introns
13
talimogene laherparepvec
12
Radiotherapy
12
Interferon alpha-2
12
spartalizumab
11
cobimetinib
10
atezolizumab
10
sargramostim
9
peginterferon alfa-2b
9
montanide ISA 51
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Melanoma
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts